On 3 June 2026, JACOBIO PHARMACEUTICALS GROUP CO., LTD. (JACOBIO) repurchased 115,500 ordinary shares on the Hong Kong Stock Exchange, paying a total consideration of HKD 498,900. The shares were bought at prices ranging from HKD 4.30 to HKD 4.32, translating into a volume-weighted average repurchase price of HKD 4.3195 per share.

The transaction reduced JACOBIO’s outstanding share count (excluding treasury shares) by 0.0147% to 783.73 million, while the total issued share capital remained unchanged at 791.76 million shares. Treasury shares rose from 7.91 million to 8.03 million, reflecting the reclassification of the repurchased stock.

The buyback was executed under the authority granted by shareholders on 10 June 2025, which permits the company to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 5.01 million shares, equivalent to 0.64% of the shares outstanding at the mandate date. All shares bought back to date have been retained as treasury shares; none have been cancelled.

In accordance with Main Board Rule 10.06(3)(a), JACOBIO is subject to a moratorium on issuing new shares or disposing of treasury shares until 3 July 2026.